Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balcinrenone + dapagliflozin dose-finding study in chronic kidney disease with albuminuria
ChiCTR2400090872Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of balcinrenone and dapagliflozin in chronic kidney disease (CKD) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Relative change in urinary albumin-to-creatinine ratio from baseline to Week 12. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2400090872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090872.